Cargando…

Head-to-Head Comparison of (68)Ga-DOTA-TATE and (68)Ga-DOTA-JR11 PET/CT in Patients With Tumor-Induced Osteomalacia: A Prospective Study

BACKGROUND: The purpose of this study is to compare the sensitivity of (68)Ga-DOTA-JR11 and (68)Ga-DOTA-TATE PET/CT for detecting the responsible tumor of tumor-induced osteomalacia (TIO) and investigate if (68)Ga-DOTA-JR11 PET/CT can identify the culprit tumor of TIO in multiple suspicious lesions...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hou, Guozhu, Zhang, Yuwei, Liu, Yu, Wang, Peipei, Xia, Weibo, Xing, Xiaoping, Huo, Li, Li, Fang, Jing, Hongli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913035/ https://www.ncbi.nlm.nih.gov/pubmed/35280786 http://dx.doi.org/10.3389/fonc.2022.811209

Ejemplares similares

Standardized image quality for (68)Ga-DOTA-TATE PET/CT
por: Cox, Christina P. W., et al.
Publicado: (2020)

PET-CT imaging of pulmonary inflammation using [(68)Ga]Ga-DOTA-TATE
por: Puuvuori, Emmi, et al.
Publicado: (2022)

Relationships between uptake of [(68)Ga]Ga-DOTA-TATE and absorbed dose in [(177)Lu]Lu-DOTA-TATE therapy
por: Stenvall, Anna, et al.
Publicado: (2022)

Physiological Biodistribution of (68)Ga-DOTA-TATE in Normal Subjects
por: Özgüven, Salih, et al.
Publicado: (2021)

[(68)Ga]Ga-DOTA-TATE uptake due to COVID-19 vaccination
por: Weiler-Sagie, Michal, et al.
Publicado: (2021)

The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors
por: Novruzov, Fuad, et al.
Publicado: (2021)

Highly variable biodistribution of (68)Ga labeled somatostatin analogues (68)Ga-DOTA-NOC and (68)Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT
por: Cheng, Monica, et al.
Publicado: (2022)

SAT-575 Radiolabeled Somatostatin Receptor Analog (86)Y-EB-TATE is Characterized by Superior Tumor Uptake Compared to (68)Ga-DOTA-TATE and (68)Ga-DOTA-JR11 in Thyroid Cancer Mice Models
por: Thakur, Shilpa, et al.
Publicado: (2019)

Application of (68)Ga-DOTA-TATE PET/CT in metastatic neuroendocrine tumor of gastrointestinal origin
por: Papadakis, Georgios Z., et al.
Publicado: (2017)

Correlations between [(68)Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [(177)Lu]Lu-DOTA-TATE
por: Bruvoll, Ragnar, et al.
Publicado: (2023)

[(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging
por: Hennrich, Ute, et al.
Publicado: (2020)

Postoperative [(68)Ga]Ga-DOTA-TATE PET/CT imaging is prognostic for progression-free survival in meningioma WHO grade 1
por: Teske, Nico, et al.
Publicado: (2023)

Head-to-head evaluation of [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma
por: Gu, Bingxin, et al.
Publicado: (2022)

A false positive 68Ga-DOTA-TATE involvement in an adrenal mass: Kaposi Sarcoma
por: Ozbas, Burak, et al.
Publicado: (2023)

Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors
por: Opalińska, Marta, et al.
Publicado: (2022)

CYP3A4 inhibitors do not influence [(68)Ga]Ga-DOTA-TATE uptake in liver tissue
por: Chahid, Youssef, et al.
Publicado: (2023)

Preparation and Biological Study of (68)Ga-DOTA-alendronate
por: Fakhari, Ashraf, et al.
Publicado: (2016)

SAT-618 Ectopic Thyroid-Stimulating Hormone-Secreting Pituitary Adenoma of the Nasopharynx Diagnosed by (68)Ga-DOTA-TATE PET/CT
por: Kim, Stephanie, et al.
Publicado: (2019)

The Impact of Total Variation Regularized Expectation Maximization Reconstruction on (68)Ga-DOTA-TATE PET/CT Images in Patients With Neuroendocrine Tumor
por: Liu, Lin, et al.
Publicado: (2022)

Diagnostic challenges in a patient with an occult insulinoma:(68 )Ga‐DOTA‐exendin‐4 PET/CT and (68)Ga‐DOTATATE PET/CT
por: Bongetti, Elisa, et al.
Publicado: (2018)

Performance of (68)Ga-DOTA-SST PET/CT, octreoscan SPECT/CT and (18)F-FDG PET/CT in the detection of culprit tumors causing osteomalacia: a meta-analysis
por: Jiang, Yuanyuan, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of (68)Ga DOTA-TATE PET/CT, (111)In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors
por: Froelich, Matthias Frank, et al.
Publicado: (2021)

Al[(18)F]F-NOTA-Octreotide Is Comparable to [(68)Ga]Ga-DOTA-TATE for PET/CT Imaging of Neuroendocrine Tumours in the Latin-American Population
por: Haeger, Arlette, et al.
Publicado: (2023)

Personal dose equivalent H(p)(0.07) during (68)Ga-DOTA-TATE production procedures
por: Wrzesień, M., et al.
Publicado: (2023)

Adventures in radiosynthesis of clinical grade [(68)Ga]Ga-DOTA-Siglec-9
por: Käkelä, Meeri, et al.
Publicado: (2018)

The role of (68)Ga-DOTA derivatives PET-CT in patients with ectopic ACTH syndrome
por: Ceccato, Filippo, et al.
Publicado: (2020)

Prevalence of Brain Incidental Lesions Detected by (68)Ga-DOTA Peptides PET/CT
por: Albano, Domenico, et al.
Publicado: (2022)

Initial Clinical Experience with (68)Ga-DOTA-NOC Prepared Using (68)Ga from Nanoceria-polyacrylonitrile Composite Sorbent-based (68)Ge/(68)Ga Generator and Freeze-dried DOTA-NOC Kits
por: Chandra, Piyush, et al.
Publicado: (2017)

Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
por: Opalinska, Marta, et al.
Publicado: (2023)

Assessment of regional pulmonary blood flow using (68)Ga-DOTA PET
por: Velasco, Carlos, et al.
Publicado: (2017)

Head-to-Head Comparison between [(68)Ga]Ga-DOTA.SA.FAPi and [(18)F]F-FDG PET/CT Imaging in Patients with Breast Cancer
por: Ballal, Sanjana, et al.
Publicado: (2023)

Pancreatic serous cystoadenoma (CSA) showing increased tracer uptake at 68-GaDOTA-peptide Positron Emission Tomography (68Ga-DOTA-peptide PET-CT): a case report
por: Nappo, Gennaro, et al.
Publicado: (2020)

The Search for an Alternative to [(68)Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of (18)F-labeled Somatostatin Analog Development
por: Waldmann, Christopher M., et al.
Publicado: (2019)

Imaging angiogenesis in patients with head and neck squamous cell carcinomas by [(68)Ga]Ga-DOTA-E-[c(RGDfK)](2) PET/CT
por: Lobeek, D., et al.
Publicado: (2020)

Results of a Prospective Trial to Compare (68)Ga-DOTA-TATE with SiPM-Based PET/CT vs. Conventional PET/CT in Patients with Neuroendocrine Tumors
por: Baratto, Lucia, et al.
Publicado: (2021)

Occupational radiation exposure assessment during the management of [(68)Ga]Ga-DOTA-TOC
por: Riveira-Martin, Mercedes, et al.
Publicado: (2022)

Monte Carlo investigation of PET [(68)Ga]Ga-DOTA-TOC activity-administration protocols for consistent image quality
por: Kalaitzidis, Philip, et al.
Publicado: (2023)

(68)Ga-PSMA and (68)Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data
por: Mapelli, Paola, et al.
Publicado: (2022)

Scale down and optimized automated production of [68Ga]68Ga-DOTA-ECL1i PET tracer targeting CCR2 expression
por: Migliari, Silvia, et al.
Publicado: (2023)

Same-day comparative protocol PET/CT-PET/MRI [(68) Ga]Ga-DOTA-TOC in paragangliomas and pheochromocytomas: an approach to personalized medicine
por: Prado-Wohlwend, Stefan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1e1rie1ut459lg91d2jvsk8hkt